BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Money on the Move: Precigen, Syros, Zhiyi and Agile Raise Capital

  As the global life sciences industry slows down, companies are gathering money through means other than VC funding. BioSpace shines a light on some of these recent transactions.

  July 7, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Intercept, Annovis and Biohaven Advance Late Phase Trials

  Intercept Pharmaceuticals, Annovis Bio and Biohaven Pharma are moving forward with late-stage Phase III clinical trials.

  July 7, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  DiaMedica Ischemic Stroke Program Hits Another Bump in the Road

  DiaMedica Therapeutics’ Phase II/III ReMEDy2 trial is on hold by the FDA because patients were experiencing severe drops in blood pressure.

  July 7, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Following Breast Cancer Fail, CytomX Slashes Workforce by 40% - UPDATED

  CytomX Therapeutics is shifting its focus to preclinical and early clinical studies, emphasizing alliances and slashing its workforce by about 40% to extend cash flow to 2025.

  July 7, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Deals

  Report: Merck in Advanced Talks to Acquire Seagen for $40B

  Merck is in late-stage discussions to acquire Seagen for about $40 billion according to a Wall Street Journal report.

  July 7, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Movers & Shakers: Adagio, Harpoon, Aravive, Nitrase and More

  Adagio, Aravive, PolyPid, Harpoon, Durect, Nitrase, Kallyope, TScan and many more made major leadership decisions this week.

  July 7, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  FDA

  FDA Grants State-Licensed Pharmacists Authority to Prescribe Pfizer’s Paxlovid

  The granting of the EUA comes with certain limitations, as the prescribing pharmacist must refer patients for clinical assessment with a physician.

  July 7, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Lysogene Gene Therapy Indicates Potential to Slow Sanfilippo Syndrome

  Lysogene’s Phase II/III trial assessing LYS-SAF302 for the treatment of MPS IIIA, also known as Sanfilippo syndrome type A, revealed positive biomarker data, spurring hope for a potential treatment.

  July 7, 2022

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Policy

  AbbVie’s Tax Structure in Crosshairs of Senate Finance Committee Report

  A Senate Finance Committee report shows the majority of AbbVie’s income is taxed through foreign subsidiaries, allowing the company to pay less than half the U.S. corporate tax rate.

  July 7, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Research Roundup: a Potential Vaccine for ALS & More

  Researchers and biotech companies are working on developing vaccines and therapies for cancer, ALS, COVID-19, obesity and psoriasis. Here’s a look at just some of them.

  July 7, 2022

   · 

  5 min read

   · 

  Mark Terry